MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, announced a partnership with...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
President-elect Donald Trump has nominated Dr. Jay Bhattacharya, a Stanford physician and economist, as the next director of the Nation...
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with ...
GSK plc (LSE/NYSE: GSK) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indi...
Kedrion Biopharma Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the company's manufacturing facility in B...
AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with ...
Eli Lilly and Company (NYSE: LLY) announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhi...
Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has approved OPUVIZ™ 40 mg/mL solution...
Exact Sciences, a leading provider of cancer screening and diagnostic tests, is proud to announce a new partnership with award-winning Hispanic actor, TV p...
Eli Lilly and Company (NYSE: LLY) announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of worsening ...
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (d...
GSK plc (LSE/NYSE: GSK) announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Bl...
Gilead Sciences, Inc. (Nasdaq: GILD) presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is stu...
© 2024 Biopharma Boardroom. All Rights Reserved.
